10-KPeriod: FY2024

JOHNSON & JOHNSON Annual Report, Year Ended Dec 29, 2024

Filed February 13, 2025For Securities:JNJ

Summary

Johnson & Johnson's 2024 10-K filing reveals a company navigating a dynamic healthcare landscape, demonstrating resilience with an increase in total sales to $88.8 billion, a 4.3% rise from the previous year, driven by strong performance in the MedTech segment and growth in specific Innovative Medicine therapeutic areas like Oncology. The company continues to invest heavily in research and development, allocating $17.2 billion to drive innovation across its two core segments: Innovative Medicine and MedTech. Despite facing ongoing challenges such as patent expirations for key products like STELARA and REMICADE, increasing competition, and a complex regulatory environment, Johnson & Johnson is strategically positioning itself for future growth through acquisitions and pipeline advancements. The company also highlights its commitment to human capital management, focusing on attracting, developing, and retaining top talent, underscored by a competitive voluntary turnover rate of 6.3% in 2024.

Financial Highlights

54 data points
Beta

Revenue

$88.82B

69.1% Gross Margin

Net Income

$14.07B

15.8% Net Margin

EPS (Diluted)

$5.79

Total Assets

$180.10B

Cash & Equivalents

$24.11B

Free Cash Flow

$19.84B

Financial Statements
Beta
Revenue$88.82B
Cost of Revenue$27.47B
Gross Profit$61.35B
R&D Expenses$1.84B
SG&A Expenses$22.87B
Operating Income$14.07B
Net Income$14.07B
EPS (Basic)$5.84
EPS (Diluted)$5.79
Shares Outstanding (Basic)2.41B
Shares Outstanding (Diluted)2.43B

Key Highlights

  • 1Total sales increased by 4.3% to $88.8 billion in fiscal year 2024.
  • 2The company invested $17.2 billion in research and development, with a focus on pipeline advancement and innovation across both Innovative Medicine and MedTech segments.
  • 3STELARA sales experienced a 4.6% decline due to biosimilar competition in Europe and the US, with further impact expected in 2025.
  • 4The MedTech segment saw a 4.8% increase in sales, boosted by the acquisition of Shockwave Medical and strong performance in the Cardiovascular franchise.
  • 5Oncology products drove significant growth in the Innovative Medicine segment, with a 17.7% increase in sales, led by DARZALEX and ERLEADA.
  • 6Johnson & Johnson successfully completed the divestiture of its remaining Kenvue stake, a process initiated in 2023, marking a strategic shift.
  • 7The company increased its dividend for the 62nd consecutive year, demonstrating a commitment to returning value to shareholders.

Frequently Asked Questions

Johnson & Johnson's growth is driven by its two main segments: Innovative Medicine and MedTech. In Innovative Medicine, oncology products like DARZALEX and ERLEADA, along with pulmonary hypertension treatments like OPSUMIT and UPTRAVI, are key growth drivers. In MedTech, the Cardiovascular franchise, significantly bolstered by the Shockwave acquisition, along with strong performance in Orthopaedics and Vision, are contributing to growth.

The filing emphasizes several key risks and challenges, including intense competition in product markets, potential loss of market exclusivity due to patent expirations and biosimilar/generic entry, significant legal proceedings (notably talc-related matters and opioid litigation), increasing regulatory scrutiny and compliance costs, and global economic and geopolitical instability impacting supply chains and market demand. Product liability, safety, and efficacy concerns are also recurring themes.

Johnson & Johnson is actively managing competition and patent expirations through continued investment in research and development to launch new products and indications, strategic acquisitions to bolster its portfolio (e.g., Shockwave Medical), and by defending its intellectual property rights through litigation. The company also focuses on lifecycle management for its existing products.

Johnson & Johnson has a strategy of actively pursuing acquisitions to strengthen its pipeline and market position, as evidenced by the acquisitions of Shockwave Medical, Ambrx Biopharma, and Proteologix in 2024. The company also completed the divestiture of its remaining stake in Kenvue, streamlining its business focus on its core healthcare segments.